Bohui Medical's ChiNext IPO has been accepted. In 2024, it ranks fourth in the Chinese market for coronary artery balloon dilation catheters.

On December 24, Guangdong Bomei Medical Technology Co., Ltd. (referred to as Bomei Medical) has had its IPO on the ChiNext Board of the Shenzhen Stock Exchange accepted. China International Capital Corporation Limited is its sponsoring institution, with plans to raise 1.7 billion yuan. According to the prospectus, Bomei Medical focuses on the research and development, production, and global sales of high-performance vascular interventional medical devices. It is a leading provider of complex vascular disease interventional treatment solutions in the global industry in terms of technology and products, as well as a leading research and production enterprise in the domestic vascular interventional balloon catheter field in terms of sales volume. In terms of product system construction, the company has formed a comprehensive product matrix covering multiple treatment scenarios, with over 50 product series. The product application areas include coronary intervention, peripheral vascular intervention, neural intervention, hemodialysis access, and interventional accessories, including various general balloon catheters, functional balloon catheters, drug balloon catheters, interventional guidewires and catheters, various thrombus handling devices, calcification handling devices, energy treatment devices, and other core product lines, fully meeting the diverse needs of clinical intervention treatment for complex vascular diseases. In terms of research and production layout, the company emphasizes global resource integration and capacity assurance. It has established 5 research and development centers and laboratories worldwide, continuously promoting core technology iteration and innovative product research and development; established 4 production bases to ensure product scale and high-quality supply; while also setting up 3 international operations centers to provide efficient operational support and service guarantees for global market expansion. In terms of market coverage, the company's products have been successfully marketed in over 100 countries and regions at home and abroad, serving tens of thousands of hospitals and medical centers globally. With stable product performance, systematic treatment solutions, and professional technical support, the company has established a good brand image in the domestic and international vascular interventional medical device market, gradually building a global market layout and customer service network. As a leading medical technology innovation platform enterprise in the field of complex vascular interventional treatment, Bomei Medical has maintained a long-term stable and high-speed development trend in both domestic and overseas markets since its sales inception. The average compound annual growth rate of revenue from 2022 to 2024 is 48.98%. The company is a long-term high-growth enterprise in the global vascular interventional industry. The company has established international operations centers in China, Europe, and the United States respectively, and has local marketing offices in multiple countries and regions, providing efficient and professional services to global customers and partners. It has already established a long-term stable marketing channel system in over 100 countries and regions globally, with over 200 overseas cooperative distributors and nearly 800 domestic cooperative distributors, serving tens of thousands of hospitals and medical centers. As a leading enterprise in the field of vascular interventional medical devices, Bomei Medical holds a leading position in the market based on its technological advantages and scalable production capacity in products such as balloon catheters. According to Frost & Sullivan data, by 2024, Bomei Medical will be the fourth largest player in the Chinese coronary artery balloon dilatation catheter market with a market share of 9.6%, and the first domestic brand; and the fifth largest player in the Chinese peripheral artery balloon dilatation catheter market with a market share of 4.7%. The proceeds of this fundraising will be invested according to the decisions approved at the second meeting of the second board of directors held on November 18, 2025, and at the third extraordinary general meeting of shareholders held on December 3, 2025. The company has always focused on the research and development, production, and global sales of high-performance vascular interventional medical devices, and this fundraising will revolve around its main business. If this stock offering is successful, the net proceeds after deducting issuance expenses will be invested in the following projects in order of priority. In terms of financials, in the years 2022, 2023, 2024, and January to June 2025, the company achieved operating income of approximately 207 million yuan, 335 million yuan, 460 million yuan, and 303 million yuan respectively; during the same period, net profit was -36.06 million yuan, 25.9914 million yuan, 76.7847 million yuan, and 35.6496 million yuan, respectively.